Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Ivermectin sales in Valle del Cauca, Colombia, patterns of AEs, and other background re López-Medina et al. 2021

Scheim et al., OSF Preprints
Mar 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19ivm.org
Analysis of several issues with López-Medina et al. including the atypical adverse effects in the control arm and population use of ivermectin.
7 meta analyses show significant improvements with ivermectin for mortality1-6, hospitalization7, recovery3, and cases3.
Currently there are 104 ivermectin for COVID-19 studies, showing 48% lower mortality [35‑59%], 35% lower ventilation [17‑50%], 40% lower ICU admission [12‑58%], 34% lower hospitalization [21‑44%], and 81% fewer cases [71‑87%].
Scheim et al., 11 Mar 2021, preprint, 1 author.
This PaperIvermectinAll
Abstract: Supplementary data re López-Medina et al. 2021 David E Scheim a Table S1. Sales of Ivermectin in liquid and capsule form in the Colombian state of Valle del Cauca, encompassing the study region, from January 2019 through November 2020.1 Units of liquid IVM were bottles each containing 5 ml of 0.6% IVM, and units of capsules were blister packs of 7 pills, 3 mg each. On July 9, 2020, a week before the LopezMedina et al. study began recruiting patients in Cali, its mayor, Jorge Iván Ospina, announced that his city would begin distributing 10,000 doses of IVM to COVID-19 patients the following day. With IVM available over the counter (OTC) in Colombia without prescription, sales of IVM quintupled in Valle del Cauca from June to July 2020. Sales of IVM during the study period of July through November 2020 totaled 154,919 units (each unit about one dose), 1.6 times the number of COVID-19 cases (95,387, see Table S2) during that period. Month Capsules Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2019 Liquid 0 0 0 0 0 0 0 0 0 0 0 0 Capsules 2,745 2,980 3,406 4,387 4,076 4,109 4,727 3,938 3,548 3,915 4,225 3,206 2020 Liquid 0 0 0 0 0 0 935 3,463 821 757 949 — 4,131 4,541 2,910 9,850 8,293 10,503 48,943 34,228 15,887 21,093 27,843 — Table S2. COVID-19 cases in the Colombian state of Valle del Cauca, encompassing the study region, from June through December 2020, by month.2 Month Number of cases June 2020 6,365 Jul 2020 14,432 Aug 2020 21,785 Sept 2020 15,172 Oct 2020 20,072 Nov 2020 23,926 Dec 2020 28,165 Table S3. Summary of adverse effects associated with IVM as reported in eTable 7 of López-Medina et al. Adverse event Ivermectin (n=275) Placebo (n=198) Dizziness (number, %) 98 (35.6%) 68 (34.3%) Diarrhea (#, %) 83 (30.2%) 65 (32.8%) Nausea #, %) 66 (24.0%) 47 (23.7%) Disturbances of vision, any (#, %) 44 (16.0%) 28 (14.1%) Photophobia (#, %) 9 (3.3%) 4 (2.0%) Blurry vision (#, %) 31 (11.3%) 23 (11.6%) David E. Scheim, PhD (email: dscheim@alum.mit.edu) is a commissioned officer in the US Public Health Service, inactive reserve. a Page 1 of 4 Figure S1. Google trends for ivermectina v. vacuna covid in the Colombian state of Valle del Cauca, encompassing the study region, during and prior to the Lopez-Medina study enrollment period of July 15 through November 30, 2020. The number of Google searches for ivermectina (Spanish for ivermectin) spiked from 2 times to 33 times that for COVID vaccine (vacuna covid) from the last week in June to the first week of July 2020. The total number of searches for ivermectina in the weeks beginning July through November 2020 was 2.7 times greater than that number for vacuna covid.3 Table S3. Timeline of breaches of boundaries between treatment and placebo groups in Lopez-Medina et al. Date Event Source Oct. 20, 2020 “On October 20, 2020, the lead pharmacist observed that a labeling error had occurred between September 29 and October 15, 2020, resulting in all patients receiving ivermectin and none receiving placebo during this time frame.” This affected 75 patients, 38 of which were randomized to receive placebo. These 75 patients were excluded in the analysis for the primary endpoint but included in several other tables presented in supplement 2. Main study paper, p. 3; study protocol, p. 43 Aug 26, 2020 This is the date through which “the placebo was a mixture of 5% dextrose in saline and 5% dextrose in distilled water.” This placebo solution was used for the..
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit